You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州漲超5% 創新BTK抑制劑斬獲FDA第二項適應症
格隆匯 09-02 09:54
格隆匯9月2日丨百濟神州(6160.HK)今早最高漲5.28%至199.1港元,總市值為2403億港元。百濟神州於2021年9月1日發表公吿,百悦澤(Brukinsa)獲得美國食品藥品監督管理局(FDA)批准用於治療成年華氏巨球蛋白血癥(WM)患者。百濟神州血液學首席醫學官黃蔚娟博士表示:“不到兩年的時間,百悦澤在已在全球範圍取得11項監管機構的批准,其中包括2項在美國的批准,這表明百悦澤正逐漸成為針對B細胞惡性腫瘤的一項卓有成效的治療選擇,並拓展其全球足跡,將有望惠及更多患者。百濟神州8月27日公佈中期業績,收入錄得7.56億美元,按年增加542%。虧損由上年同期6.99億美元,收窄至4.14億美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account